BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BMS-986506 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of BMS-986506\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07195682-11189@assetmemo.bio
DTSTAMP:20261121T005559Z
DTSTART;VALUE=DATE:20300503
DTEND;VALUE=DATE:20300504
SUMMARY:BMS-986506: Phase 1 readout est. (NCT07195682)
DESCRIPTION:BMS-986506\, phase 1.\nStudy: A First-in-Human Study of BMS-986
 506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)\
 nEstimated primary completion: 3 May 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/bms-986506#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07195682
URL:https://assetmemo.bio/drug/bms-986506#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
